Top

Journal of Endocrinological Investigation

Published in:

01-09-2015 | Original Article

The lung endothelin system: a potent therapeutic target with bosentan for the amelioration of lung alterations in a rat model of diabetes mellitus

Authors: A. Cayir, R. A. Ugan, A. Albayrak, D. Kose, E. Akpinar, Y. Cayir, H. T. Atmaca, Z. Bayraktutan, M. Kara

Published in: Journal of Endocrinological Investigation | Issue 9/2015

Abstract

Purpose

The aim of this study is to show the effect of a new mechanism on endothelin (ET) receptors in the physiopathology of diabetes-related pulmonary injury. We tested the hypothesis that dual ET-1 receptor antagonism via bosentan can reverse diabetes-induced lung injury.

Methods

The rats (24 male) were separated into four groups: group 1 (HEALTHY): Control group; group 2 (DM): Streptozotocin 60 mg/kg (i.p.); group 3 (DM + BOS-1): Diabetes + bosentan 50 mg/kg per-os; group 4 (DM + BOS-2): Diabetes + bosentan 100 mg/kg per-os. The bosentan treatment was initiated immediately after the onset of STZ-induced diabetes and continued for 6 weeks.

Results

In the treatment group, SOD activity was significantly increased, although GSH and MDA levels and TNF-α and TGF-β gene expression were decreased. Bosentan 50 mg/kg and bosentan 100 mg/kg showed a significantly down-regulatory effect on ET-1, ET-A, and ET-B mRNA expression.

Conclusions

In conclusion, increased endothelin levels in the lung associated with diabetes may be one cause of endothelial dysfunction, cytokine increase, and oxidant/antioxidant imbalance in the pathogenesis of complications that may develop during diabetes. With its multiple effects, bosentan therapy may be an effective option against complications that may develop in association with diabetes.

Karalliedde J, Gnudi L (2014) Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Renal Assoc. doi:10.1093/ndt/gfu405

Dave S (2014) Mesenchymal stem cells derived in vitro transdifferentiated insulin-producing cells: a new approach to treat type 1 diabetes. Adv Biomed Res 3:266. doi:10.4103/2277-9175.148247 PubMedCentralCrossRefPubMed

Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith G (2009) Type 2 diabetes in the child and adolescent. Pediatr Diabetes 10(Suppl 12):17–32. doi:10.1111/j.1399-448.2009.00584.x CrossRefPubMed

Simsek DG, Aycan Z, Ozen S, Cetinkaya S, Kara C, Abali S, Demir K, Tunc O, Ucakturk A, Asar G, Bas F, Cetinkaya E, Aydin M, Karaguzel G, Orbak Z, Siklar Z, Altincik A, Okten A, Ozkan B, Ocal G, Semiz S, Arslanoglu I, Evliyaoglu O, Bundak R, Darcan S (2013) Diabetes care, glycemic control, complications, and concomitant autoimmune diseases in children with type 1 diabetes in Turkey: a multicenter study. J Clin Res Pediatr Endocrinol 5(1):20–26. doi:10.4274/Jcrpe.893 PubMedCentralCrossRefPubMed

Demirel F, Tepe D, Kara O, Esen I (2013) Microvascular complications in adolescents with type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 5(3):145–149. doi:10.4274/Jcrpe.994 PubMedCentralCrossRefPubMed

Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, Nathan D, Vinicor F (2003) Implications of the United kingdom prospective diabetes study. Diabetes Care 26(Suppl 1):S28–S32PubMed

Gilbert RE (2013) Endothelial loss and repair in the vascular complications of diabetes: pathogenetic mechanisms and therapeutic implications. Circ J 77(4):849–856CrossRefPubMed

Genuth S (2006) Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 12(Suppl 1):34–41. doi:10.4158/EP.12.S1.34 CrossRefPubMed

Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32(10):1901–1903. doi:10.2337/dc09-0109 PubMedCentralCrossRefPubMed

10.

Popov D, Simionescu M (2001) Structural and transport property alterations of the lung capillary endothelium in diabetes. Ital J Anat Embryol 106(2 Suppl 1):405–412PubMed

11.

Vojtkova J, Ciljakova M, Michnova Z, Turcan T (2012) Chronic complications of diabetes mellitus related to the respiratory system. Pediatr Endocrinol Diabetes Metab 18(3):112–115PubMed

12.

Weynand B, Jonckheere A, Frans A, Rahier J (1999) Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration 66(1):14–19. doi:10.1159/000029331 CrossRefPubMed

13.

Hsia CC, Raskin P (2007) Lung function changes related to diabetes mellitus. Diabetes Technol Ther 9(Suppl 1):S73–S82. doi:10.1089/dia.2007.0227 PubMed

14.

Kuziemski K, Specjalski K, Jassem E (2011) Diabetic pulmonary microangiopathy—fact or fiction? Endokrynol Pol 62(2):171–176PubMed

15.

Pitocco D, Fuso L, Conte EG, Zaccardi F, Condoluci C, Scavone G, Incalzi RA, Ghirlanda G (2012) The diabetic lung–a new target organ? Rev Diabet Stud 9(1):23–35. doi:10.1900/RDS.2012.9.23 PubMedCentralCrossRefPubMed

16.

Scano G, Filippelli M, Romagnoli I, Mancini M, Misuri G, Duranti R, Rosi E (2000) Hypoxic and hypercapnic breathlessness in patients with type I diabetes mellitus. Chest 117(4):960–967CrossRefPubMed

17.

Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, Chiossi E, Landzberg M, Invest B (2006) Bosentan therapy in patients with Eisenmenger syndrome—a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114(1):48–54. doi:10.1161/Circulationaha.106.630715 CrossRefPubMed

18.

Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF, Simonneau G (2004) Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170(11):1212–1217. doi:10.1164/rccm.200404-445OC CrossRefPubMed

19.

Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J (2005) Bosentan therapy for portopulmonary hypertension. Eur Respir J 25(3):502–508. doi:10.1183/09031936.05.00080804 CrossRefPubMed

20.

Rafnsson A, Bohm F, Settergren M, Gonon A, Brismar K, Pernow J (2012) The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia 55(3):600–607. doi:10.1007/s00125-011-2415-y CrossRefPubMed

21.

Hauber HP, Blaukovitsch M (2010) Current and future treatment options in idiopathic pulmonary fibrosis. Inflamm Allergy Drug Targets 9(3):158–172CrossRefPubMed

22.

Cosentino F, Luscher TF (1998) Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 32(Suppl 3):S54–S61PubMed

23.

Eleftheriadis T, Antoniadi G, Pissas G, Liakopoulos V, Stefanidis I (2013) The renal endothelium in diabetic nephropathy. Ren Fail 35(4):592–599. doi:10.3109/0886022X.2013.773836 CrossRefPubMed

24.

Eringa EC, Serne EH, Meijer RI, Schalkwijk CG, Houben AJ, Stehouwer CD, Smulders YM, van Hinsbergh VW (2013) Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes. Rev Endocr Metab Disord 14(1):39–48. doi:10.1007/s11154-013-9239-7 CrossRefPubMed

25.

Feener EP, King GL (2001) Endothelial dysfunction in diabetes mellitus: role in cardiovascular disease. Heart Fail Monit 1(3):74–82PubMed

26.

Lee SH, Channick RN (2005) Endothelin antagonism in pulmonary arterial hypertension. Semin Respir Crit Care Med 26(4):402–408. doi:10.1055/s-2005-916155 CrossRefPubMed

27.

Shao D, Park JE, Wort SJ (2011) The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res 63(6):504–511. doi:10.1016/j.phrs.2011.03.003 CrossRefPubMed

28.

Arison RN, Ciaccio EI, Glitzer MS, Cassaro JA, Pruss MP (1967) Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin. Diabetes 16(1):51–56CrossRefPubMed

29.

Hasanein P, Shahidi S (2010) Effects of combined treatment with vitamins C and E on passive avoidance learning and memory in diabetic rats. Neurobiol Learn Mem 93(4):472–478. doi:10.1016/j.nlm.2010.01.004 CrossRefPubMed

30.

de Souza LF, Barreto F, da Silva EG, Andrades ME, Guimaraes EL, Behr GA, Moreira JC, Bernard EA (2007) Regulation of LPS stimulated ROS production in peritoneal macrophages from alloxan-induced diabetic rats: involvement of high glucose and PPARgamma. Life Sci 81(2):153–159. doi:10.1016/j.lfs.2007.04.035 CrossRefPubMed

31.

Ghorbani A, Omrani GR, Hadjzadeh MA, Varedi M (2013) Proinsulin C-peptide inhibits lipolysis in diabetic rat adipose tissue through phosphodiestrase-3B enzyme. Horm Metab Res 45(3):221–225. doi:10.1055/s-0032-1323764 PubMed

32.

Ghorbani A, Varedi M, Hadjzadeh MA, Omrani GH (2010) Type-1 diabetes induces depot-specific alterations in adipocyte diameter and mass of adipose tissues in the rat. Exp Clin Endocrinol Diabetes 118(7):442–448. doi:10.1055/s-0030-1247566 CrossRefPubMed

33.

Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95(2):351–358CrossRefPubMed

34.

Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25(1):192–205CrossRefPubMed

35.

Sun Y, Oberley LW, Li Y (1988) A simple method for clinical assay of superoxide dismutase. Clin Chem 34(3):497–500PubMed

36.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25(4):402–408. doi:10.1006/meth.2001.1262 CrossRefPubMed

37.

Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P (2001) Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 27(4 Pt 1):436–447PubMed

38.

Sarman B, Toth M, Somogyi A (1998) Role of endothelin-1 in diabetes mellitus. Diabetes Metab Rev 14(2):171–175CrossRefPubMed

39.

Ergul A (2011) Endothelin-1 and diabetic complications: focus on the vasculature. Pharmacol Res 63(6):477–482. doi:10.1016/j.phrs.2011.01.012 CrossRefPubMed

40.

Comellas AP, Briva A (2009) Role of endothelin-1 in acute lung injury. Transl Res 153(6):263–271. doi:10.1016/j.trsl.2009.02.007 PubMedCentralCrossRefPubMed

41.

Ross B, D’Orleans-Juste P, Giaid A (2010) Potential role of endothelin-1 in pulmonary fibrosis: from the bench to the clinic. Am J Respir Cell Mol Biol 42(1):16–20. doi:10.1165/rcmb.2009-0175TR CrossRefPubMed

42.

Schneider MP, Boesen EI, Pollock DM (2007) Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47:731–759. doi:10.1146/annurev.pharmtox.47.120505.105134 PubMedCentralCrossRefPubMed

43.

Cardillo C, Campia U, Bryant MB, Panza JA (2002) Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106(14):1783–1787CrossRefPubMed

44.

McAuley DF, Nugent AG, McGurk C, Maguire S, Hayes JR, Johnston GD (2000) Vasoconstriction to endogenous endothelin-1 is impaired in patients with Type II diabetes mellitus. Clin Sci 99(3):175–179. doi:10.1042/Cs20000005 CrossRefPubMed

45.

Zhou Y, Mitra S, Varadharaj S, Parinandi N, Zweier JL, Flavahan NA (2006) Increased expression of cyclooxygenase-2 mediates enhanced contraction to endothelin ETA receptor stimulation in endothelial nitric oxide synthase knockout mice. Circ Res 98(11):1439–1445. doi:10.1161/01.RES.0000224120.52792.10 CrossRefPubMed

46.

Climent B, Fernandez N, Sanz E, Sanchez A, Monge L, Garcia-Villalon AL, Dieguez G (2005) Enhanced response of pig coronary arteries to endothelin-1 after ischemia-reperfusion. Role of endothelin receptors, nitric oxide and prostanoids. Eur J Pharmacol 524(1–3):102–110. doi:10.1016/j.ejphar.2005.09.002 CrossRefPubMed

47.

Fonseca C, Abraham D, Renzoni EA (2011) Endothelin in pulmonary fibrosis. Am J Respir Cell Mol Biol 44(1):1–10. doi:10.1165/rcmb.2009-0388TR CrossRefPubMed

48.

Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358(9288):1119–1123. doi:10.1016/S0140-6736(01)06250-X CrossRefPubMed

49.

Prakash A, Perry CM (2002) Bosentan. Am J Cardiovasc Drugs 2(5):335–343 (discussion 343)CrossRefPubMed

50.

Araz O, Demirci E, Yilmazel Ucar E, Calik M, Pulur D, Karaman A, Yayla M, Altun E, Halici Z, Akgun M (2013) Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study. Multidiscip Respir Med 8(1):74. doi:10.1186/2049-6958-8-74 PubMedCentralCrossRefPubMed

51.

Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630):2093–2100. doi:10.1016/S0140-6736(08)60919-8 CrossRefPubMed

52.

Elmarakby AA, Sullivan JC (2012) Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 30(1):49–59. doi:10.1111/j.1755-5922.2010.00218.x CrossRefPubMed

53.

Navarro-Gonzalez JF, Jarque A, Muros M, Mora C, Garcia J (2009) Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev 20(2):165–173. doi:10.1016/j.cytogfr.2009.02.005 CrossRefPubMed

54.

Nishimura M, Obayashi H, Mizuta I, Hara H, Adachi T, Ohta M, Tegoshi H, Fukui M, Hasegawa G, Shigeta H, Kitagawa Y, Nakano K, Kaji R, Nakamura N (2003) TNF, TNF receptor type 1, and allograft inflammatory factor-1 gene polymorphisms in Japanese patients with type 1 diabetes. Hum Immunol 64(2):302–309CrossRefPubMed

55.

Gonzalez-Clemente JM, Mauricio D, Richart C, Broch M, Caixas A, Megia A, Gimenez-Palop O, Simon I, Martinez-Riquelme A, Gimenez-Perez G, Vendrell J (2005) Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. Clin Endocrinol 63(5):525–529. doi:10.1111/j.1365-2265.2005.02376.x CrossRef

56.

Yoshida A, Yoshida S, Khalil AK, Ishibashi T, Inomata H (1998) Role of NF-kappa B-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 39(7):1097–1106PubMed

57.

Gupta S, Gambhir JK, Kalra O, Gautam A, Shukla K, Mehndiratta M, Agarwal S, Shukla R (2013) Association of biomarkers of inflammation and oxidative stress with the risk of chronic kidney disease in Type 2 diabetes mellitus in North Indian population. J Diabetes Complications 27(6):548–552. doi:10.1016/j.jdiacomp.2013.07.005 CrossRefPubMed

58.

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M (2013) Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 715(1–3):246–255. doi:10.1016/j.ejphar.2013.05.014 CrossRefPubMed

59.

Bowen T, Jenkins RH, Fraser DJ (2013) MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. J Pathol 229(2):274–285. doi:10.1002/path.4119 CrossRefPubMed

60.

Samarakoon R, Overstreet JM, Higgins PJ (2013) TGF-beta signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell Signal 25(1):264–268. doi:10.1016/j.cellsig.2012.10.003 PubMedCentralCrossRefPubMed

61.

Gao Y, Xu X, Ding K, Liang Y, Jiang D, Dai H (2013) Rapamycin inhibits transforming growth factor beta1-induced fibrogenesis in primary human lung fibroblasts. Yonsei Med J 54(2):437–444. doi:10.3349/ymj.2013.54.2.437 PubMedCentralCrossRefPubMed

62.

Song X, Liu W, Xie S, Wang M, Cao G, Mao C, Lv C (2013) All-trans retinoic acid ameliorates bleomycin-induced lung fibrosis by downregulating the TGF-beta1/Smad3 signaling pathway in rats. Lab Invest 93(11):1219–1231. doi:10.1038/labinvest.2013.108 CrossRefPubMed

63.

El Gazaerly H, Elbardisey DM, Eltokhy HM, Teaama D (2013) Effect of transforming growth factor Beta 1 on wound healing in induced diabetic rats. Int J Health Sci (Qassim) 7(2):160–172CrossRef

64.

Sipal S, Halici Z, Kiki I, Polat B, Albayrak A, Albayrak F, Karakus E, Aksak S, Ozturk B, Gundogdu C (2012) Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy. J Mol Histol 43(6):723–735. doi:10.1007/s10735-012-9441-z CrossRefPubMed

65.

Halici Z, Bilen H, Albayrak F, Uyanik A, Cetinkaya R, Suleyman H, Keles ON, Unal B (2009) Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes? Eur J Pharmacol 614(1–3):146–152. doi:10.1016/j.ejphar.2009.04.042 CrossRefPubMed

66.

Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133(5):687–694. doi:10.1038/sj.bjp.0704131 PubMedCentralCrossRefPubMed

67.

Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB (2011) Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22(6):1144–1151. doi:10.1681/ASN.2010101049 PubMedCentralCrossRefPubMed

68.

Shepler B, Nash C, Smith C, Dimarco A, Petty J, Szewciw S (2012) Update on potential drugs for the treatment of diabetic kidney disease. Clin Ther 34(6):1237–1246. doi:10.1016/j.clinthera.2012.04.026 CrossRefPubMed

69.

Obrosova IG (2005) Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signal 7(11–12):1543–1552. doi:10.1089/ars.2005.7.1543 CrossRefPubMed

70.

Vincent AM, Russell JW, Low P, Feldman EL (2004) Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 25(4):612–628. doi:10.1210/Er.2003-0019 CrossRefPubMed

71.

Ziegler D, Sohr CGH, Nourooz-Zadeh J (2004) Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care 27(9):2178–2183. doi:10.2337/diacare.27.9.2178 CrossRefPubMed

72.

Pennathur S, Heinecke JW (2007) Oxidative stress and endothelial dysfunction in vascular disease. Curr Diab Rep 7(4):257–264CrossRefPubMed

73.

Wen Y, Skidmore JC, Porter-Turner MM, Rea CA, Khokher MA, Singh BM (2002) Relationship of glycation, antioxidant status and oxidative stress to vascular endothelial damage in diabetes. Diabetes Obes Metab 4(5):305–308CrossRefPubMed

74.

Uyanik A, Unal D, Uyanik MH, Halici Z, Odabasoglu F, Altunkaynak ZB, Cadirci E, Keles M, Gundogdu C, Suleyman H, Bayir Y, Albayrak M, Unal B (2010) The effects of polymicrobial sepsis with diabetes mellitus on kidney tissues in ovariectomized rats. Ren Fail 32(5):592–602. doi:10.3109/08860221003759478 CrossRefPubMed

75.

Suys B, de Beeck LO, Rooman R, Kransfeld S, Heuten H, Goovaerts I, Vrints C, de Wolf D, Matthys D, Manuel-y-Keenoy B (2007) Impact of oxidative stress on the endothelial dysfunction of children and adolescents with type 1 diabetes mellitus: protection by superoxide dismutase? Pediatr Res 62(4):456–461. doi:10.1203/PDR.0b013e318142581a CrossRefPubMed

76.

Goyal R, Singhai M, Faizy AF (2011) Glutathione peroxidase activity in obese and nonobese diabetic patients and role of hyperglycemia in oxidative stress. J Midlife Health 2(2):72–76. doi:10.4103/0976-7800.92529 PubMedCentralPubMed

77.

Likidlilid A, Patchanans N, Poldee S, Peerapatdit T (2007) Glutathione and glutathione peroxidase in type 1 diabetic patients. J Med Assoc Thai 90(9):1759–1767PubMed

78.

Yayla M, Halici Z, Unal B, Bayir Y, Akpinar E, Gocer F (2014) Protective effect of Et-1 receptor antagonist bosentan on paracetamol induced acute liver toxicity in rats. Eur J Pharmacol 726C:87–95. doi:10.1016/j.ejphar.2014.01.022 CrossRef

79.

80.

Albayrak A, Uyanik MH, Odabasoglu F, Halici Z, Uyanik A, Bayir Y, Albayrak F, Albayrak Y, Polat B, Suleyman H (2011) The effects of diabetes and/or polymicrobial sepsis on the status of antioxidant enzymes and pro-inflammatory cytokines on heart, liver, and lung of ovariectomized rats. J Surg Res 169(1):67–75. doi:10.1016/j.jss.2009.09.055 CrossRefPubMed

81.

Nakhjavani M, Esteghamati A, Nowroozi S, Asgarani F, Rashidi A, Khalilzadeh O (2010) Type 2 diabetes mellitus duration: an independent predictor of serum malondialdehyde levels. Singapore Med J 51(7):582–585PubMed

82.

Reis JS, Veloso CA, Volpe CM, Fernandes JS, Borges EA, Isoni CA, Dos Anjos PM, Nogueira-Machado JA (2012) Soluble RAGE and malondialdehyde in type 1 diabetes patients without chronic complications during the course of the disease. Diab Vasc Dis Res 9(4):309–314. doi:10.1177/1479164111436316 CrossRefPubMed

83.

Singh G, Sharma B, Jaggi AS, Singh N (2014) Efficacy of bosentan, a dual ETA and ETB endothelin receptor antagonist, in experimental diabetes induced vascular endothelial dysfunction and associated dementia in rats. Pharmacol Biochem Behav 124:27–35. doi:10.1016/j.pbb.2014.05.002 CrossRefPubMed

84.

Jiang JH, Yuen V, Xiang H, McNeill JH (2006) Improvement in cardiac function of diabetic rats by bosentan is not associated with changes in the activation of PKC isoforms. Mol Cell Biochem 282(1–2):177–185. doi:10.1007/S11010-006-1926-1 CrossRefPubMed

85.

Sachidanandam K, Portik-Dobos V, Kelly-Cobbs AI, Ergul A (2010) Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes. Can J Physiol Pharm 88(6):616–621. doi:10.1139/Y10-034 CrossRef

Title: The lung endothelin system: a potent therapeutic target with bosentan for the amelioration of lung alterations in a rat model of diabetes mellitus
Authors: A. Cayir
R. A. Ugan
A. Albayrak
D. Kose
E. Akpinar
Y. Cayir
H. T. Atmaca
Z. Bayraktutan
M. Kara
Publication date: 01-09-2015
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 9/2015
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-015-0282-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2015

Bone health in type 1 diabetes: focus on evaluation and treatment in clinical practice

How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology

Evaluation of function and structure of arterial wall in girls and young women with Turner syndrome

Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy

The acromegalic voice of Tango: Don Edmundo Rivero

Comparison of conventional l-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage